CA - Biolog, Inc., a biotech company in Hayward, California,
today announced a 35% expansion of its facilities. That increase
accommodates the growth of the company's product line in microbiology,
and also provides room for the company's move into the fast
growing field of functional genomics.
adds laboratory, warehouse and manufacturing capacity and
is designed to meet FDA QS and GMP requirements at Biolog's
facility, located at 21124 Cabot Blvd., Hayward, CA.
core technology relates to cellular physiology. During its
15-year history, the company has developed a worldwide reputation
as a leader in systems for microbial identification and characterization.
Now Biolog is using its expertise in cellular physiology to
develop products for functional genomics. "These new products
represent a shift in the paradigm from molecular-level to
cellular-level testing, and a move from genomics and proteomics
to 'phenomics,'" said Tim Mullane, Biolog's president and
CEO. "Our products will fill major gaps in functional genomics
research and will reduce both time and costs related to expensive
drug trials." Biolog's proprietary Phenotype MicroArray™ (PM)
system, will be used by researchers in the genomics field
and by researchers developing anti-microbial agents.
designed our new facility to accommodate the expected increase
in PM business from pharmaceutical and biotechnology companies.
This involved expanding our laboratory space by 100% and expanding
our customer support capability."
genomics is the science of determining the connection between
specific genes and the ultimate traits expressed in the microorganism,
plant or animal (such as drug resistance, drought tolerance
or disease susceptibility). These observable traits are called
of genomics, has employed tools such as gene sequencing and
"gene chips" to produce a wealth of genetic information. A
higher level of analysis has involved the study of the proteins
that genes produce. These studies, "proteomics," typically
employ electrophoresis and mass spectrometry. But while the
study of proteins adds understanding and clues into the consequences
of genetic changes, it still falls short of providing the
direct link between genes and phenotypic traits. Biolog's
products will fill that gap.
genomic and proteomic studies are performed at the molecular
level, Biolog's technology provides information at the higher
cellular level, and it is cost-effective and scalable
for high-throughput applications. The technology provides
a powerful tool for pharmaceutical companies' drug discovery
programs, which are faced with the daunting task of making
sense of the immense amount of information resulting from
gene sequencing. By studying the impact on cells of a genetic
change or a drug application, scientists can rapidly discard
unproductive avenues of research and focus on those that are
most promising, and they can do so before conducting costly
and time-consuming studies in live animals or plants. The
savings in wasted research dollars can be enormous.
information contact Biolog, Inc. at (510) 785-2564 or visit
the Biolog website at www.biolog.com.